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Abstract
Background: Recent preclinical and phase I studies have reported that rebamipide decreased the severity of
chemoradiotherapy-induced oral mucositis in patients with oral cancer. This placebo-controlled randomized phase II
study assessed the clinical benefit of rebamipide in reducing the incidence of severe chemoradiotherapy-induced
oral mucositis in patients with head and neck cancer (HNC).
Methods: Patients aged 20–75 years with HNC who were scheduled to receive chemoradiotherapy were enrolled.
Patients were randomized to receive rebamipide 2% liquid, rebamipide 4% liquid, or placebo. The primary endpoint
was the incidence of grade ≥ 3 oral mucositis determined by clinical examination and assessed by central review
according to the Common Terminology Criteria of Adverse Events version 3.0. Secondary endpoints were the time
to onset of grade ≥ 3 oral mucositis and the incidence of functional impairment (grade ≥ 3) based on the
evaluation by the Oral Mucositis Evaluation Committee.
Results: From April 2014 to August 2015, 97 patients with HNC were enrolled, of whom 94 received treatment.
The incidence of grade ≥ 3 oral mucositis was 29% and 25% in the rebamipide 2% and 4% groups, respectively,
compared with 39% in the placebo group. The proportion of patients who did not develop grade ≥ 3 oral
mucositis by day 50 of treatment was 57.9% in the placebo group, whereas the proportion was 68.0% in the
rebamipide 2% group and 71.3% in the rebamipide 4% group. The incidences of adverse events potentially related
to the study drug were 16%, 26%, and 13% in the placebo, rebamipide 2%, and rebamipide 4% groups,
respectively. There was no significant difference in treatment compliance among the groups.
Conclusions: The present phase II study suggests that mouth washing with rebamipide may be effective and safe
for patients with HNC receiving chemoradiotherapy, and 4% liquid is the optimal dose of rebamipide.
Trial registration: ClinicalTrials.gov under the identifier NCT02085460 (the date of trial registration: March 11, 2014).
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Background
Oral mucositis is an adverse event (AE) frequently in-
duced by radiotherapy and chemotherapy during cancer
treatment. Common symptoms are pain, dysphagia, dys-
geusia, and infection, which can considerably affect the
patient’s quality of life. Additionally, oral mucositis is a
risk factor for sepsis in patients with low neutrophil
count secondary to cancer treatment toxicity. During
cancer treatment, aggravation of oral mucositis leads to
dose reduction, suspension, or discontinuation of treat-
ment, thereby affecting the patient prognosis [1, 2].
Approximately 600,000 patients worldwide are cur-
rently undergoing cancer treatment with radiotherapy
and/or chemotherapy, and are at risk of developing oral
mucositis [3]. Reportedly, oral mucositis develops in
more than 90% of patients receiving chemoradiotherapy
(CRT) for head and neck cancer (HNC) [4]. Thus, there
is a particularly strong demand for the development of
prophylactic and therapeutic agents for oral mucositis.
Oral mucositis results from direct cell injury caused by
chemotherapy or radiotherapy. Tissue injury is amplified
by reactive oxygen species, proinflammatory cytokines
and pathways, and metabolic byproducts of colonizing
microorganisms [1]. Some agents targeting these under-
lying mechanisms have been evaluated for oral mucositis
treatment. Palifermin, a keratinocyte growth factor-1,
has been approved by the Food and Drug Administra-
tion for stem cell transplantation; however, it has not
been approved for HNC, although it was shown to
decrease oral mucositis effectively [5, 6]. Rebamipide,
originally developed by Otsuka Pharmaceutical Co., Ltd.
(Tokyo, Japan) for gastritis, gastric ulcer, and xero-
phthalmia enhances endogenous prostaglandin produc-
tion in the gastric mucosa and inhibits free radical
production [7–9]. Additionally, it has been shown to
inhibit neutrophil activation and inflammatory cytokine
production by mononuclear cells, gastric mucosa, and
vascular endothelial cells, and to inhibit other inflamma-
tory reactions [10–12].
In pilot studies performed to assess the efficacy of
rebamipide liquid for CRT-induced oral mucositis in pa-
tients with oral cancer, rebamipide decreased the sever-
ity of mucositis [13, 14]. Additionally, rebamipide liquid
administered at doses of 1%, 2%, and 4%, resulted in a
dose-dependent reduction of total injury extension and
tongue ulcerations in a rat model of irradiation-induced
oral mucositis [15].
In accordance with these preclinical and phase I stud-
ies, rebamipide 2% and 4% liquids were chosen as
potential prophylactic and therapeutic agents for CRT-
induced oral mucositis in patients with HNC. The aim
of this phase II exploratory study was to compare the
incidence of oral mucositis in patients receiving reba-
mipide 2% and 4% liquids, or placebo.
Methods
Study design
This was a multicenter, randomized, double-blind,
placebo-controlled, parallel-group, dose-ranging phase II
study. This study is registered at ClinicalTrials.gov under
the identifier NCT02085460 (the date of trial registra-
tion: March 11, 2014). The institutional review boards of
the 20 participating institutions (Additional file 1) ap-
proved the study protocol. All study procedures were
conducted in accordance with the 1964 Declaration of
Helsinki and its later amendments, and in compliance
with the Good Clinical Practice Guidelines specified by
the Ministry of Health, Labour and Welfare of Japan.
Dynamic allocation was used to randomize patients,
with stratification based on the purpose of CRT for
HNC (definitive or post-operative) and primary site (oral
cavity, nasopharynx, oropharynx, hypopharynx, or
larynx). Subject enrollment and random study drug allo-
cation were performed using the Interactive Web
Response System. The subjects and investigators were
kept masked to the treatment allocation until the end of
the study. A sample size of 90 subjects was planned
based on the feasibility of patient enrollment. Patients
were randomly assigned to one of three groups, with 30
patients each: placebo, rebamipide 2% liquid, and reba-
mipide 4% liquid.
Patients
All study participants provided written informed consent
at enrollment, 10 to 28 days prior to the initiation of
CRT. Screening was performed based on the inclusion
and exclusion criteria (Additional file 1). Briefly, patients
between the ages of 20 and 75 years with histopatho-
logical diagnosis of primary tumor in the nasopharynx,
oropharynx, hypopharynx, larynx, or oral cavity, regard-
less of the stage, scheduled to undergo definitive or post-
operative CRT with ≥50 Gy irradiation to the buccal
mucosa, floor of the mouth, tongue, or soft palate, with
an Eastern Cooperative Oncology Group (ECOG) per-
formance status (PS) score of 0 or 1, life expectancy of
at least 3 months, without a history of chemotherapy,
radiotherapy, or CRT for HNC, who could perform
mouth washing and swallow fluids, and could attend
follow-up visits, were included in this study.
Study treatment
The study drugs consisted of placebo (same formulation
as rebamipide liquids) and rebamipide 2% and 4% liq-
uids, which were given 6 times daily, preferably once
after every meal, twice between meals, and once before
bedtime. Patients were instructed to wash their mouth
with 5 mL of the study drug for at least 30 s and then
swallow it. The use of all other drugs for oral mucositis
treatment, including oral ointment of corticosteroid, was
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prohibited. The only local treatments permitted in this
study were oral aerosol spray for xerostomia, local anti-
biotics for the treatment of infection (e.g., amphotericin
b or miconazole), and analgesic agents (e.g., xylocaine,
opioid analgesics, and acetaminophen).
The treatment started 3 days prior to the initiation of
CRT and continued for another 77 days. Cisplatin at 80–
100 mg/m2 was administered thrice at 3-week intervals.
Radiotherapy at ≤2.2 Gy/fraction was administered once
daily, with 5 fractions per week, up to a total dose of
≥60 Gy. Withdrawal from the study was accepted before
Day 77 if oral mucositis resolved completely, if oral mu-
cositis did not develop 1 week after CRT completion, or
if a patient requested to withdraw from the study.
Post-treatment examinations, including the assessment
of adverse events and observation of oral mucositis, were
performed 1 week after completion of CRT or 1 week
after the patient decided to withdraw from the study.
Subjects who underwent post-treatment examination
were defined as subjects who completed the study.
Oral assessment
Investigators who had undergone specific training
assessed the severity of oral mucositis twice every week.
To evaluate the severity of oral mucositis objectively, the
clinical findings of the oral mucosa as well as functional
disorders and symptomatic aspects were recorded in the
Oral Mucositis Assessment Sheet (Additional file 1) by
each investigator. Photographic documentation of the
oral mucosa was also submitted by each investigator,
3 days before or 57 days after initiation of CRT, or at the
time of withdrawal. The Oral Mucositis Assessment
Sheet allows the relevant findings at each site in the oral
cavity (10 sites in total) to be recorded separately. The
Oral Mucositis Assessment Sheets and photographic
documentation were then reviewed by the Oral Mucosi-
tis Evaluation Committee to grade the severity of oral
mucositis according to the Common Terminology
Criteria for Adverse Events (CTCAE) 3.0. Grade 3 for
clinical examination was defined as “confluent ulcera-
tions or pseudomembranes (bleeding with minor
trauma),” and grade 3 for function/symptoms was de-
fined as “symptomatic and unable to adequately ingest
food or hydrate orally.”
Endpoints
The primary endpoint was the incidence of grade ≥ 3
oral mucositis assessed via clinical examination accord-
ing to the CTCAE version 3.0. Secondary endpoints
were time to onset of grade ≥ 3 oral mucositis and the
incidence of functional impairment (grade ≥ 3) based
on the Oral Mucositis Evaluation Committee evalu-
ation. Exploratory endpoints were total cisplatin dose
and compliance with radiotherapy during the study.
Pharmacokinetics was assessed in terms of safety in the
patients who ingested the drug. The AEs were assessed
and classified based on the MedDRA system organ
class and preferred term.
Statistical analysis
The full analysis set (FAS) comprised patients who re-
ceived the study drug or placebo at least once and whose
efficacy data were collected immediately after beginning
the treatment. The safety set (SS) comprised those who
received the study drug or placebo at least once and
whose safety data were collected at least once after be-
ginning the treatment. The per protocol set (PPS) con-
sisted of patients who were compliant with the protocol.
Patients who did not satisfy the inclusion/exclusion cri-
teria, did not receive adequate radiotherapy, or did not
comply with the prescription of combination therapy, or
show drug compliance were excluded from the PPS.
The incidence of oral mucositis in each group was
compared using the chi-square test. A step-down strat-
egy was used for the between-group comparison, adjust-
ing for multiplicity. Comparisons were made first
between the rebamipide 4% and the placebo groups, and
then between the rebamipide 2% and placebo groups.
The Cochran-Armitage test was used as a trend test. All
statistical analyses were performed using SAS 9.2 (SAS
Institute Japan, Tokyo, Japan).
Results
Patient characteristics
Of 97 subjects randomized between April 2014 and
August 2015, approximately 50% of the subjects had a
primary tumor in the oropharynx, and approximately
20% of the subjects had a history of surgery for head and
neck cancer. However, as a whole, the baseline charac-
teristics of patients were well balanced between the
treatment groups (Table 1).
Patient disposition
A total of 94 patients received the study drug and were
included in the FAS and the SS. Sixty-two (66%) patients
completed the study. The most frequent reason for study
withdrawal in all three groups was patient request (22%,
33%, and 16% in the placebo, rebamipide 2% and 4%
groups, respectively) (Fig. 1).
Incidence of oral mucositis
In the FAS, the incidence of grade ≥ 3 oral mucositis de-
termined by clinical examination and assessed by the
Oral Mucositis Evaluation Committee was 29% and 25%
in the rebamipide 2% and 4% groups, respectively, com-
pared with 39% in the placebo group (Fig. 2a). In a trend
test, a decrease in the incidence of grade ≥ 3 oral muco-
sitis was observed with an increasing concentration of
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rebamipide liquid; however, this decrease was not statis-
tically significant (p = 0.2399). In the PPS, the incidence
of grade ≥ 3 oral mucositis was 45% (n = 20), 36%
(n = 22), and 27% (n = 30) in the placebo, rebamipide
2%, and rebamipide 4% groups, respectively, with no sig-
nificant difference (p = 0.1779) (Fig. 2b). The incidence
of functional impairment (Grade 3 or higher) was 29%,
36%, and 22% in the placebo, rebamipide 2% and 4%
groups, respectively (Fig. 2c).
Time to onset of grade ≥ 3 oral mucositis
The rebamipide 2% and 4% groups showed a trend of
delaying the time to onset of grade ≥ 3 oral mucositis as
compared with the placebo group, although the differ-
ence between the groups was not statistically significant
(Fig. 3). For instance, the proportion of patients who did
not develop grade ≥ 3 oral mucositis by day 50 of treat-
ment was 57.9% in the placebo group, whereas the pro-
portion was 68.0% in the rebamipide 2% group and
71.3% in the rebamipide 4% group.
Treatment compliance
Oral retention and swallowing compliance for the study
drugs were better in the rebamipide groups than in the
placebo group. The proportion of patients whose oral re-
tention and swallowing compliance was ≥80% was high-
est in the rebamipide 4% group, being 78.1%. In
contrast, the proportion in the rebamipide 2% group was
the same as that in the placebo group (58.1%). No sig-
nificant differences in the total doses of cisplatin and the
total radiation dose were observed among the groups
(Table 2), suggesting that compliance with CRT was not
influenced by the study drug.
Pharmacokinetics
Peak plasma concentration (mean ± standard deviation) of
rebamipide on day 64 was 241 ± 160 ng/mL in the reba-
mipide 2% group (n = 11) and 568 ± 235 ng/mL in the
rebamipide 4% group (n = 15) (Additional file 2: Fig. S1).
No remarkable inter-patient variation was observed. The
plasma concentration of rebamipide did not reach a suffi-
cient level to induce the biochemical effects of
rebamipide.
Safety
The incidence of AEs potentially related to the study
drug was 16% (5/31), 26% (8/31), and 13% (4/32) in the
placebo, rebamipide 2%, and rebamipide 4% groups, re-
spectively. Nausea and vomiting were the most fre-
quently reported AEs (Table 3). All patients experienced
at least one AE and there was no significant difference
in the incidence among the groups (data not shown).
Discussion
Basic oral care is considered common sense in the man-
agement of radiation-induced mucositis. However, a sys-
tematic oral care program alone is insufficient to
decrease the incidence of severe oral mucositis in pa-
tients with HNC undergoing CRT [16]. Therefore, there
is a strong demand for the development of prophylactic
and therapeutic agents against oral mucositis. This phase
II study evaluated the suppressive effect and safety of
rebamipide liquid for CRT-induced oral mucositis in pa-
tients with HNC and assessed the optimal dose of reba-
mipide liquid.
As reported by the investigators and evaluated by the
Oral Mucositis Evaluation Committee, we observed a
decreased incidence of grade ≥ 3 oral mucositis in
patients treated with rebamipide 2% and 4% liquids
compared with those treated with placebo; however,
these differences were not statistically significant. Fur-
thermore, there was a trend towards a prolongation in
the time to onset of grade ≥ 3 oral mucositis and a de-
crease in functional impairment in patients treated with
rebamipide 4% liquid compared with those treated with
Table 1 Patient baseline characteristics
Placebo
(N = 31)
Rebamipide 2%
(N = 31)
Rebamipide 4%
(N = 32)
Male (%) 25 (81) 26 (84) 26 (81)
Age (mean ± SD) (%) 60 ± 9 61 ± 12 62 ± 9
ECOG PS (PS = 0) (%) 28 (90) 28 (90) 28 (88)
Primary site
Oral cavity (%) 2 (6) 4 (13) 4 (13)
Nasopharynx (%) 6 (19) 7 (23) 6 (19)
Oropharynx (%) 17 (55) 14 (45) 15 (47)
Hypopharynx (%) 5 (16) 6 (19) 6 (19)
Larynx (%) 1 (3) 0 1 (3)
Prior surgery for head
and neck cancer
(with prior surgery) (%)
7 (23) 7 (23) 6 (19)
TNM staging of primary tumor
T1 6 (19) 9 (29) 4 (13)
T2 14 (45) 10 (32) 15 (47)
T3 7 (23) 4 (13) 5 (16)
T4 4 (13) 8 (26) 8 (25)
N0 7 (23) 3 (10) 3 (9)
N1 8 (26) 3 (10) 8 (25)
N2 13 (42) 23 (74) 20 (63)
N3 3 (10) 2 (6) 1 (3)
Radiation technique
3D–CRT 4 (13) 9 (29) 7 (22)
IMRT 27 (87) 22 (71) 25 (78)
Data are presented as number and percent [n (%)]
SD standard deviation, ECOG PS Eastern Cooperative Oncology Group
performance status, 3D–CRT three-dimensional conformal radiation therapy,
IMRT Intensity-Modulated Radiation Therapy
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placebo. These results may suggest a clinical benefit of
rebamipide in reducing the incidence of severe oral mu-
cositis induced by CRT. Recently, a small randomized,
double-blind, placebo-controlled trial was conducted in
patients with oral cancer treated with CRT at a total ra-
diation dose of 40 Gy and concomitant weekly chemo-
therapy with docetaxel 10 mg/m2. The results revealed
that the incidence of grade ≥ 3 mucositis (World Health
Organization grade 3 or 4) in patients receiving rebami-
pide 0.1% was 33% (p = 0.036), compared with 83% in
patients receiving placebo [9]. Even though the mean
total radiation dose in our study was higher than that in
their study, our patients had a lower incidence of
grade ≥ 3 mucositis with rebamipide 4% liquid.
Previous reports showed that a rebamipide concentra-
tion ≥ 10 μM was required to exhibit its inhibitory effect
on the production of radical and inflammatory cytokines
[8, 9, 11, 12]. In this study, the plasma concentration in
the rebamipide 4% group was 568 ± 235 ng/mL
(1.53 μM). This suggests that the concentration reached
after swallowing rebamipide, and its subsequent intes-
tinal absorption, was insufficient to achieve a biologically
active plasma concentration. We hypothesize that the
local concentration of rebamipide achieved through
mouth washing plays a major role in the clinical effect
of rebamipide on oral mucositis. Furthermore, in pa-
tients who underwent definitive CRT, the response rate
was 62.5%, 62.5%, and 69.2% in the placebo, rebamipide
Fig. 2 Incidence of grade ≥ 3 oral mucositis based on clinical examination by full analysis set (FAS) (a) and by per protocol set (PPS) (b); c
Incidence of functional impairment (grade ≥ 3)
Fig. 1 Patient disposition by individual treatment group. AE, adverse event
Yokota et al. BMC Cancer  (2017) 17:314 Page 5 of 8
2% and 4% groups, respectively. No new lesions were
observed in all patients who underwent postoperative
CRT at the point of the first scan. These results may
suggest that rebamipide has no remarkable effect on
local disease control despite its free radical scavenging
effect on reactive oxygen species.
Although all patients reported at least one AE, there
were no significant differences in the incidence of AEs
among the groups. Therefore, no concerns were raised
regarding the safety profiles of either rebamipide 2% or
rebamipide 4% liquid. The safety profile of rebamipide
suggests that ingestion of rebamipide 2% and 4% liquid
formulations is safe.
The efficacy and safety profiles suggest that the opti-
mal dose of rebamipide for the next phase of the study
is rebamipide 4% liquid. Unfortunately, no statistically
significant differences were observed between the
rebamipide liquids and placebo with regard to the sup-
pressive effect on CRT-induced oral mucositis. Several
factors may explain this negative result. The first is the
poor compliance in the rebamipide 2% and 4% groups,
and the placebo group. The most common reason for
Fig. 3 Time to onset of grade ≥ 3 oral mucositis. The y-axis shows the percentage of patients who have not developed grade ≥ 3 mucositis
Table 2 Treatment compliance
Number of doses Placebo
N = 31
Rebamipide 2%
N = 31
Rebamipide 4%
N = 32
297 ± 168 278 ± 171 343 ± 135
Retention compliance,a n (%)
≥ 80% 18 (58.1) 18 (58.1) 25 (78.1)
≥ 50% to <80% 6 (19.4) 7 (22.6) 6 (18.8)
< 50% 7 (22.6) 6 (19.4) 1 (3.1)
Swallowing rate,b n (%)
≥ 80% 9 (29.0) 13 (41.9) 14 (43.8)
≥ 50% to <80% 6 (19.4) 8 (25.8) 6 (18.8)
< 50% 16 (51.6) 10 (32.3) 12 (37.5)
Total doses of cisplatin (mg/m2) 213 ± 73 192 ± 66 233 ± 61
The total radiation dose (Gy) 58 ± 20 55 ± 22 63 ± 13
Frequency of interruption of radiotherapy
0 times 28 (90.3) 29 (93.5) 30 (93.8)
1 times 3 (9.7) 2 (6.5) 1 (3.1)
2 times 0 0 0
3 times 0 0 0
Number of doses, total doses of cisplatin, and total radiation dose are expressed as mean ± standard deviation
aRetention means keeping the investigational medicinal product for 30 s or more in the mouth. Retention compliance (%) = Total number of investigational
medicinal product (IMP) retention ÷ [(end date of IMP administration - start date of IMP administration +1) × 6] × 100
bSwallowing rate (%) = Total number of IMP swallowed ÷ [(end date of IMP administration - start date of IMP administration +1) × 6] × 100
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discontinuation of treatment was related with the taste
and smell of the formulation. For instance, in a recent
patient survey of Japanese patients with liver cirrhosis,
poor adherence to treatment with branched-chain
amino acid granules was significantly associated with
disinterest and distaste owing to the flavor and volume
of the medication [17]. Their finding and ours suggest
that patients are highly susceptible to the smell and
taste of medications that require frequent intake.
Therefore, the taste of the medication needs to be im-
proved in the future. The second factor is the small
sample size. A small sample size and poor compliance
with the study drug may lead to statistically under-
powered results. Further, in the present study, subjects
who discontinued treatment were not followed-up
after the treatment discontinuation. Therefore, there is
a possibility that compliance with CRT and the inci-
dence of grade ≥ 3 oral mucositis were not assessed
accurately in the subjects who discontinued the treat-
ment. Because of these factors and the lack of statis-
tical significance, the benefit of rebamipide might be
underestimated.
There were almost no differences in functional and
symptomatic aspects between the placebo and reba-
mipide groups. The functional and symptomatic as-
pects are not only affected by mucositis, but also by a
combination of multiple factors, including dysgeusia,
salivary gland secretion, and swallowing dysfunction
associated with irradiation of the pharyngeal con-
strictor muscles. Therefore, control of mucositis only
by rebamipide may not be sufficient to prevent func-
tional impairment.
Conclusions
Our study indicates that mouth washing with rebami-
pide liquid may be potentially effective and safe for pa-
tients with HNC receiving CRT. The efficacy and safety
profiles suggest that 4% liquid is the optimal dose of
rebamipide. Based on the present results and those of
previous pilot studies [13, 14], we consider that it is
highly relevant to conduct the next phase of study with
a larger sample size.
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